Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chiara Cremolini

Showing results (131-140 of 284) with videos related to

Pageof 29
Sort By:
Clinical Colorectal Cancer|May 30, 2020
Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional AnalysisDaniele Rossini, Marco Maria Germani, Filippo Pagani, et al.
The New England Journal of Medicine|October 23, 2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancerFotios Loupakis, Chiara Cremolini, Gianluca Masi, et al.
British Journal of Cancer|July 13, 2021
CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studiesRoberto Moretto, Daniele Rossini, Veronica Conca, et al.
European Journal of Cancer (Oxford, England : 1990)|August 31, 2024
BRAF + EGFR +/- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancerMargherita Ambrosini, David Tougeron, Dominik Modest, et al.
Cancers|November 25, 2023
Primary Tumor Resection in Synchronous Metastatic Colorectal Cancer Patients Treated with Upfront Chemotherapy plus Bevacizumab: A Pooled Analysis of TRIBE and TRIBE2 StudiesValentina Fanotto, Daniele Rossini, Mariaelena Casagrande, et al.
Future Oncology (London, England)|August 14, 2023
The prognostic value of radiomic features in liver-limited metastatic colorectal cancer patients from the TRIBE2 studyFederica Marmorino, Lorenzo Faggioni, Daniele Rossini, et al.
Plos One|July 18, 2013
Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumabFotios Loupakis, Chiara Cremolini, Dongyun Yang, et al.
European Journal of Cancer (Oxford, England : 1990)|December 21, 2021
Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancerGiovanni Randon, Rossana Intini, Chiara Cremolini, et al.
Cancer Treatment Reviews|January 11, 2022
Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literaturePasquale Lombardi, Daniele Rossini, Veronica Crespi, et al.
Journal for Immunotherapy of Cancer|January 2, 2023
Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancerVincenzo Nasca, Francesco Barretta, Francesca Corti, et al.
Pageof 29

Showing results (131-140 of 284) with videos related to

Sort By:
Pageof 29
Clinical Colorectal Cancer|May 30, 2020
Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional AnalysisDaniele Rossini, Marco Maria Germani, Filippo Pagani, et al.
The New England Journal of Medicine|October 23, 2014
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancerFotios Loupakis, Chiara Cremolini, Gianluca Masi, et al.
British Journal of Cancer|July 13, 2021
CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studiesRoberto Moretto, Daniele Rossini, Veronica Conca, et al.
European Journal of Cancer (Oxford, England : 1990)|August 31, 2024
BRAF + EGFR +/- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancerMargherita Ambrosini, David Tougeron, Dominik Modest, et al.
Cancers|November 25, 2023
Primary Tumor Resection in Synchronous Metastatic Colorectal Cancer Patients Treated with Upfront Chemotherapy plus Bevacizumab: A Pooled Analysis of TRIBE and TRIBE2 StudiesValentina Fanotto, Daniele Rossini, Mariaelena Casagrande, et al.
Future Oncology (London, England)|August 14, 2023
The prognostic value of radiomic features in liver-limited metastatic colorectal cancer patients from the TRIBE2 studyFederica Marmorino, Lorenzo Faggioni, Daniele Rossini, et al.
Plos One|July 18, 2013
Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumabFotios Loupakis, Chiara Cremolini, Dongyun Yang, et al.
European Journal of Cancer (Oxford, England : 1990)|December 21, 2021
Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancerGiovanni Randon, Rossana Intini, Chiara Cremolini, et al.
Cancer Treatment Reviews|January 11, 2022
Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literaturePasquale Lombardi, Daniele Rossini, Veronica Crespi, et al.
Journal for Immunotherapy of Cancer|January 2, 2023
Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancerVincenzo Nasca, Francesco Barretta, Francesca Corti, et al.
Pageof 29